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vious history of cardiovascular disease or equivalent was sub-
stantially higher (p < 0.001) for those treated with atorvastatin
(53.54%) than for those treated with any other statin; lovastatin:
29.49%; simvastatin: 42.58%; pravastatin: 52%; ﬂuvastatin:
41.1%; 2) Atorvastatin was used in patients with a signiﬁcantly
higher number of CVRF (2) than that of lovastatin: 1.7; 
simvastatin: 1.8; pravastatin: 1.9 and ﬂuvastatin: 1.8 (p <
0.0001); and 3) the use of Atorvastatin with a higher proportion
of subjects under optimal cLDL control in comparison with all
the other statins as a group (52.8% vs. 46.47%; p < 0.01) and
individually considered (lovastatin 50.7%; simvastatin 41.3%;
pravastatin 43%; atorvastatin 52.8%; ﬂuvastatin 39%). CON-
CLUSIONS: In daily clinical practice in Spain, atorvastatin is
used in patients with more cardiovascular risk factors and worse
risk proﬁle, in comparison with other commercialized statins,
however, treatment with atorvastatin is related with a higher pro-
portion of patients with appropriate control of cLDL as per ATP
III criteria. Even in a high quality environment, there is room for
improving the average proportion with appropriate control of
CVRF.
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OBJECTIVE: To determine cardiovascular risk factors proﬁle
(CVRF) and the percentage of patients reaching goals as deﬁned
by ATP III, in a population of patients with dyslipidemia and/or
hypertension, in daily clinical practice. METHODS: A total of
9001 patients with dyslipidemia and/or hypertension, assigned
to four Catalan primary care centres were selected. 1) CVRF
proﬁle; 2) a classiﬁcation of the patients by LDL cholesterol
(cLDL) levels, as for the ATP III criteria; and 3) the percentage
of patients reaching optimal control goals, were estimated for
the three groups: hypertensives without dyslipidemia (HT
without DL), patients with dyslipidemia without HT (DL
without HT) and hypertensives with dyslipidemia (HT with DL).
RESULTS: 1) Cardiovascular heart disease or equivalent was
present in 36.8%. A 7.9% had one CVRF; 29.2% two CVRF;
43.2% three CVRF; 17.1% four CVRF and 2.1% ﬁve CVRF. 2)
Percentage with opitmal cLDL control was 40.1% for HT
without DL, 29.6% for DL without HT and 27.8% for HT with
DL. 3) A 27.1% simultaneously had optimal levels of cLDL and
blood pressure (BP). That percentage was 30.1% for HT without
DL; 27.5% for DL without HT and 21.9% for DL with HT (p
< 0.0001). CONCLUSIONS: More than one-third (36.8%) of
patients with hypertension and/or dyslipidemia have a previous
history of cardiovascular disease or equivalent. Almost two-
thirds (62.9%) presented with one or more additional CVRF.
Despite high quality standards, the proportion of patients with
optimal levels of cLDL and BP (27.1%) is small and there is
much room for improvement.
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OBJECTIVE: To assess costs related to hypertension in the
elderly and in patients less than 65 years of age with uncontrolled
hypertension in Poland. METHODS: The time horizon of the
analysis was 12 months and a retrospective approach was
applied. Calculations were made from the societal perspective
and third party payer perspective. Both direct medical costs and
indirect costs were included. A detailed cost analysis was made
for the 4392 patients with uncontrolled hypertension, compar-
ing elderly patients with patients under 65. Resource utilisation
data were derived from a scientiﬁc project conducted among GPs
in the whole of Poland in the year 2000. Data concerning the
efﬁciency of blood pressure control were gathered from the
Polish epidemiological study. Unit costs were obtained from 
the Polish National Health Fund. RESULTS: Among the 8.4
million hypertensive patients in Poland 57% receive active treat-
ment, 80% (3.8 million) of which do not reach the appropriate
blood pressure target. The distribution of the direct medical costs
in patients with uncontrolled hypertension was as follows: drugs
29%, laboratory, diagnostic tests 13%, hospitalisation 27% and
physicians’ consultations 31%. Taking the societal perspective,
the direct medical costs were higher by 8% in the elderly uncon-
trolled patients and amounted to €249.30 but indirect costs were
more than 12 times lower in the elderly as compared to €241.85
in patients under 65. The total costs in the elderly uncontrolled
patients assessed from the third party payer perspective were
higher by 14% and amounted to €201.74. CONCLUSION: The
costs related to uncontrolled hypertension constitute a consider-
able economic burden. Uncontrolled hypertension might be the
cause of increasing expenditure on health care in the near future.
Wider use of more efﬁcient antihypertensive drugs may help to
avoid this phenomenon.
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OBJECTIVE: To compare costs in patients with non-
complicated arterial hypertension to costs in hypertensive
patients suffering from concomitant diseases in Poland.
METHODS: The time horizon of the analysis was 12 months
and a retrospective approach was applied. Calculations were
made from the societal perspective and third party payer per-
spective. Both direct medical and indirect costs were included.
Costs in patients (n = 2532) with non-complicated hypertension
were compared to costs observed in hypertensive patients (n =
2702) with co-existing: hypercholesterolemia, diabetes mellitus,
coronary artery disease, heart failure and a combination of these.
Resource utilisation data were derived from a scientiﬁc project
conducted among GPs in the whole of Poland in the year 2000.
The unit costs were obtained from the Polish National Health
Fund. RESULTS: The annual direct medical costs in a patient
with non-complicated hypertension amounted to €184.12. The
costs increase observed in a patient with concomitant disease was
as follows: 5% in diabetes mellitus, 6% in hypercholesterolemia,
16% in heart failure, and 19% in coronary artery disease. The
highest cost increase was related to hypertensive patients suffer-
ing from coronary artery disease co-existing with diabetes (63%)
and heart failure (80%). The costs of hospitalisation and
doctors’ consultations were identiﬁed as crucial cost drivers in
all evaluated groups. The indirect costs contribution in the total
costs was the highest (57%) in the coronary artery disease group
and the lowest (26%) in the diabetes group and it respectively
amounted to €288.26 and €68.49 per patient per year respec-
tively, in comparison with €128.87 in the group with non-
complicated hypertension. CONCLUSION: A wider use of anti-
hypertensive drugs more effective in terms of blood pressure
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control and a positive inﬂuence on organ complications related
to hypertension may result in avoidance of huge costs due the
complications incidences.
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OBJECTIVE: To assess the cost-effectiveness of antihypertensive
treatment with nebivolol, atenolol or ACE inhibitor monother-
apy in 60-year and 70-year-old patients with moderate hyper-
tension in Germany. METHODS: Using a decision-analytic
Markov model, we determined incremental cost-effectiveness
ratios (ICER) of treatment with nebivolol, atenolol and ACE
inhibitor monotherapy from third party payers’ perspective over
a 5-year time horizon. Effects on diastolic blood pressure were
obtained from a pooled analysis of published randomized clini-
cal trials using response and compliance data. The 5-year
absolute risk for an initial coronary, cerebrovascular event or
cardiovascular death was computed using the gender speciﬁc
algorithm based on Framingham Heart Study data. Costs were
derived from published tariff lists. Direct medical costs per
patient included cost of drug treatment over the 5-year period
and cost of acute care for coronary and cerebrovascular events.
RESULTS: The comparison of nebivolol vs. ACE inhibitors
showed that 3.5 (60-year-old men) and 3.4 (70-year-old men) life
years more per 100 patients could be gained with nebivolol. With
higher incremental costs, ICER for nebivolol versus ACE
inhibitors was €2025 (60-year-old men) and €1824 (70-year-old
men). In comparison to atenolol, 6.3 (60-year-old men) and 5.7
(70-year-old men) life years more per 100 patients could be
gained. ICER for nebivolol versus atenolol was €4672 (60-year-
old men) and €4704 (70-year-old men) per life-year gained. For
women, the number of incremental life years gained was lower.
ICER for nebivolol versus ACE inhibitors were €2347 (60-year-
old women) and €1,904 (70-year-old women) and for nebivolol
versus atenolol €11,648 (60-year-old women) and €9060 (70-
year-old women) per life-year gained. CONCLUSION: Based on
our decision analysis, the use of nebivolol was more effective
than antihypertensive therapy with ACE inhibitors and atenolol.
Antihypertensive treatment with nebivolol is a cost-effective
treatment option from third party payer’s perspective in
Germany in the selected patient groups.
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OBJECTIVE: Indapamide is one of the most frequently pre-
scribed diuretics in Greece and the most expensive too. The
purpose of this study was to compare the cost-effectiveness of
indapamide with propranolol, amlodipine, enalapril and irbe-
sartan in the management of mild-to-moderate hypertension in
Greece. METHODS: A cost-effectiveness analysis was per-
formed from a third-party payer perspective, in 2004 Euros (€).
A decision analysis model was developed to compare the ﬁve
alternative interventions. Clinical inputs were derived from ran-
domized controlled trials and cost data from public sources. The
evaluation of the cost of managing hypertension includes the cost
of drug therapy, monitoring, treating side-effects, poor compli-
ance and switching. The DerSimonian and Laird method was
used for the meta-analysis. The time horizon was ﬁve years.
Future costs and health beneﬁts were discounted at 5%. Exten-
sive sensitivity analyses were performed. RESULTS: Old and new
drugs provided similar protection against total mortality and
major CVD events in mild-to-moderate uncomplicated hyper-
tension. The ﬁve-years total treatment cost was €550.99,
€582.04, €864.32, €622.30, and €1283.99 for indapamide, pro-
pranolol, amlodipine, enalapril and irbesartan respectively and
the estimated total cost to prevent one major cardiovascular
event was €16,239.77, €17,154.91, €25,474.88, €18,341.68 and
€37,844.09 respectively. Sensitivity analyses conﬁrmed the lower
cost-effectiveness ratio of indapamide in comparison with pro-
pranolol, amlodipine, enalapril or irbesartan. CONCLUSION:
In the management of mild-to-moderate hypertension in Greece,
indapamide is more cost-effective than propranolol, amlodipine,
enalapril or irbesartan. The results of this study support the last
recommendations of the Joint National Committee and the 
International Society of Hypertension. Indapamide should be
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OBJECTIVES: To calculate the cost-effectiveness of daily treat-
ment of 160mg valsartan/25mg HCTZ for systemic arterial
hypertension (SAH) as compared with 16mg candesartan/
12.5mg HCTZ and with 80mg telmisartan/12.5mg HCTZ.
METHODS: The information used in this model originates from
a study comparing therapeutic effectiveness of valsartan/HCTZ
in combination versus combinations of candarstan/HCTZ and
of telmisartan/HCTZ for the treatment of SAH. Patients received
16mg candesartan/12.5mg HCTZ or 80mg telmisartan/12.5mg
HCTZ daily for 4 weeks. The Mean Sitting Diastolic Blood
Presure (MSDBP) was measured at the beginning and at the end
of the 4-weeks treatment. Those patients who were not con-
trolled using either of these regimens (MSDBP° 90mmHg)
were given daily doses of 160mg valsartan/25mg HCTZ for a
further 4 weeks. RESULTS: Patients who received 16mg can-
desartan/12.5mg HCTZ or 80mg telmisartan/12.5mg HCTZ
showed a 28% success rate in achieving a MSDBP <90mm Hg.
Patients who received 160mg valsartan/25mg HCTZ demon-
strated a 74% success rate for the same parameter. Furthermore,
the reduction in MSDBP in those patients who received 160mg
valsartan/25mg HCTZ was 10.3mm Hg greater than that
obtained in the ﬁrst phase of the study (p < 0.0001). The only
important difference in the use of medical resources related to
these therapies was the cost of the medicines involved. The
monthly anti-hypertensive treatment cost for the 160mg valsar-
tan/25mg HCTZ combination was the lowest of the three com-
binations at $295.71 Mexican pesos (US$26.88) as compared
with $354.54 Mexican pesos (US$32.23) for the 16mg can-
desartan/12.5mg HCTZ combination and $428.51 Mexican
pesos (US$38.95) for 80mg telmisartan/12.5mg HCTZ. CON-
CLUSIONS: The combination of 160mg valsartan/25mg HCTZ
is more effective and less expensive than either 16mg candesar-
tan/12.5mg HCTZ or 80mg telmisartan/12.5mg HCTZ.
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